Evidence map›Paper›PMID 36909522›Full record

ArticlebioRxiv : the preprint server for biology2023

CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment.

Musleh M Muthana, Xuexiang Du, Mingyue Liu, Xu Wang, Wei Wu, Chunxia Ai, Lishan Su, Pan Zheng, Yang Liu

Open access · greenFull text readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Musleh M MuthanaDivision of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine; Baltimore, MD 21201, USA.
Xuexiang DuDivision of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine; Baltimore, MD 21201, USA.
Mingyue LiuDivision of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine; Baltimore, MD 21201, USA.
Xu WangDivision of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine; Baltimore, MD 21201, USA.
Wei WuDivision of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine; Baltimore, MD 21201, USA.
Chunxia AiDivision of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine; Baltimore, MD 21201, USA.
Lishan SuDivision of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine; Baltimore, MD 21201, USA.
Pan ZhengDivision of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine; Baltimore, MD 21201, USA.
Yang LiuDivision of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine; Baltimore, MD 21201, USA.
University of Maryland, Baltimore · US

Funding

Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapyR01AI154722 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SU, LISHAN · 2020 to 2024
$2.6M
Immune Mechanisms of Elevated Liver Diseases During HIV InfectionR01DK119937 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SU, LISHAN · 2018 to 2022
$1.9M
NIAID NIH HHS R01 AI154722NIDDK NIH HHS R01 DK119937
6 · The paper itself

Abstract

Germline CTLA-4 deficiency causes severe autoimmune diseases characterized by dysregulation of Foxp3

Identifiers

PMID36909522
PMCPMC10002750
OpenAlexW4323074140

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read63
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.